Profile

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Key Products

Viz.ai One is an AI-powered care coordination platform designed to revolutionize the way patient care is delivered across a healthcare system for acute and chronic diseases. Viz.ai is a system of action, empowering multidisciplinary care teams to coordinate care to ensure earlier detection of disease with regulatory-cleared AI algorithms and better patient outcomes. Viz.ai One advances end-to-end care pathways supporting neurology, vascular, cardiology, trauma, emergency department, and radiology teams.

Customer Insights

“Since integrating Viz.ai into our network our team has been able to quickly assess and provide timely care to our pulmonary embolism patients. By closely monitoring our metrics and implementing best practices, we’re committed to improve our throughput and deliver exceptional care to all of our patients.” Dr. Elias Iliadis, Interventional Cardiologist at Cooper University Healthcare

“Nowadays we instantaneously get the scans that we need on a telephone, on an iPhone, we can see those scans and we can use our expert eyes to really make the definitive diagnosis,” Dr. Colin McDonald said. “It saves time, it also saves unnecessary transfers, and it just improves patient’s outcome.”

“Viz HCM is detecting almost 80 to 90 percent of new cases within our system. And that’s important because many patients linger through the health system, just carrying a diagnosis or symptoms for a long time, but just being treated with standard medication that doesn’t really change at all their health trajectory.” Dr. Jorge Silva, UCSD

Key Executives

• Chris Mansi, MD, CEO and Co-Founder


• David Kizner, General Counsel and Chief Privacy Officer


• Dawn Sprague, Vice President of People


• Gad Sakin, Chief Product Officer


• Jayme Strauss, RN, MSN, MBA, SCRN, Chief Clinical Officer


• Jieun Choe, Chief Marketing Officer


• Julie Skaff, Chief Operating Officer


• Kurt Blasena, Chief Revenue Officer


• Steve Sweeny, Vice President, Business Development and Strategy

Board Members

• Chris Mansi, MD, CEO and Co-Founder, Viz.ai


• Mamoon Hamid, Partner at Kleiner Perkins


• Mark Laret, President & CEO Emeritus at UCSF Health


• Rory O’Driscoll, Partner at Scale Venture Partners

Investors

Last round of funding was Series D for $100 million announced in April 2022.

Investors include Kleiner Perkins, Google Ventures, Scale Ventures, Insight Partners, Tiger Global, Susa, CRV, Sozo Ventures.

News and Press Releases

Oct 2023: Viz.ai Honored by Goldman Sachs for Entrepreneurship (Read)

Sep 2023: Viz.ai Announces Expansion into Outpatient Ambulatory Centers to Accelerate Clinical Trial Recruitment in Heart Failure (Read)

Sep 2023: New Clinical Data Supports Viz.ai Solution for Improved Pulmonary Embolism Detection and Care Coordination (Read)

Sep 2023: Viz.ai to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (Read)

Aug 2023: Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms (Read)

To know more about their latest news and press release, visit here.

Competitors

Tempus

Corporate Responsibility

Their mission is to increase access to life-saving treatments. They democratize access to advanced medical treatments with AI algorithms trained by very diverse data sets from data sourced all over the world and creating a broad, connected network of hospitals, including those in underserved, rural areas. They continuously work towards reducing disparities in healthcare access and ensuring that all populations can benefit from advancements in medical technology. This is evidenced by numerous publications that demonstrate savings in time to treatment, reduction in disability, and increased access to care.